Icosavax

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

by
Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology

Icosavax creates virus-like particles using technology licensed from the University of Washington’s Institute for Protein Design. (Icosavax photo) Seattle-based Icosavax filed for an IPO just four years after it started at the University of Washington. The company, a spin-out of the UW’s Institute for Protein Design, develops vaccines that resemble naturally occurring viruses. Icosavax initiated … Read more

Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology

by
Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology

Icosavax creates virus-like particles using technology licensed from the University of Washington’s Institute for Protein Design. (Icosavax photo) New financing: At a moment when everyone is talking about vaccines, a Seattle-based biotech company taking an unusual approach to vaccine production raised $ 100 million in a Series B round. The startup creates computerized, virus-like particles … Read more